CUA Astellas Research Grant Program now accepting proposals for 2013
MARKHAM, ON, Dec. 12, 2012 /CNW/ - Improving patient care is the
ultimate goal of a research grant program, designed to support Canadian
scientific discovery and innovation in urology.
Researchers are invited to submit a proposal to the CUA Astellas
Research Grant Program, a joint initiative of the Canadian Urological
Association (CUA) and Astellas Pharma Canada, Inc. (Astellas).
This is the second year of the grant program, which supports
peer-reviewed research and promotes excellence in urological research.
Astellas has pledged $750,000 CND over a period of five years to
support Canadian investigators in urology.
For the 2013 competition, the primary focus is to support research in
functional urology, including overactive bladder (OAB), lower urinary
tract symptoms (LUTS), pelvic floor disorders, voiding dysfunctions, and neurogenic
bladder. The secondary focus is to support other urology research
areas such as urologic cancer and other community-based research.
Three research grants will be awarded (each with a maximum value of
$50,000 CDN) based on scientific validity, integrity, clinical
relevance, and feasibility. Grant recipients are expected to
demonstrate improved understanding of the specific research area and/or
directly contribute to improving patient care.
Dr. Blayne Welk, a 2012 grant recipient based at University of Western
Ontario, says the funding has provided him with an exciting opportunity
to pursue his research interests among patients with neurogenic bladder
"I am sure the CUA Astellas grant's commitment to support voiding
dysfunction research will inspire new researchers with an interest in
this area and build on existing high-quality Canadian research," Welk
Dr. Ben Chew, also a 2012 grant recipient, strongly encourages other
Canadian urology researchers to apply to the grant program. He says his
laboratory at the University of British Columbia is most appreciative
of this funding, adding that it "really relays the commitment that
Astellas has to supporting urologists, research, and ultimately
patients and their health."
"With these funds, it will allow us to fund enough experiments to obtain
important preliminary data and then apply for national funding agencies
such as CIHR or NSERC for further funding," says Chew, whose research
is on the physiology of ureteral peristalsis and the effects of stone
passage and ureteral stent insertion. "Without money from the CUA
Astellas Research Grant, our research would not be able to expand."
Michael Tremblay, President of Astellas Pharma Canada, Inc., says
Astellas is proud to support the efforts of researchers in the Canadian
urology community because of the direct impact their work will have on
patient care and health.
"Quality of life is a huge issue for patients with urologic conditions,"
says Tremblay. "Through Astellas' grant partnership with the CUA, it is
our hope that the resulting research will ultimately lead to
ground-breaking new therapies that will transform patient lives - that
is what it is all about."
For more information about the CUA Astellas Research Grant, including
eligibility criteria and the application process, please visit
www.cua.org or www.astellas.ca. The deadline to submit a research
proposal is January 13, 2013, at 5 p.m. EST.
About the Canadian Urological Association (CUA)
The CUA Mission is to represent and provide a voice for all Canadian
urologists and to foster dedication of all members of the profession
toward ensuring the highest possible standard of urologic care for
The goals of the CUA are:
To foster and promote excellence in urologic practice through education
To provide leadership in promoting evidence based clinical practice
through the development of practice guidelines.
To foster and promote life-long learning by Canadian urologists through
continuous professional development.
To provide leadership in public education for urologic diseases.
To represent Canadian urology in developing and fostering partnerships
while maintaining the highest educational and ethical standards.
To represent the Canadian urologic community in relationships with
national and international medical societies.
More information about CUA can be found at www.cua.org
About Astellas Pharma Canada, Inc.
Astellas Pharma Canada, Inc., headquartered in Markham, ON, is a
Canadian affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a
pharmaceutical company dedicated to improving the health of people
around the world through the provision of innovative and reliable
The organization is committed to becoming a global category leader in
focused areas by combining outstanding R&D and marketing capabilities.
In Canada, Astellas has an intense commercial focus on five therapeutic
areas - Urology, Immunology, Infectious Disease, Dermatology and
For more information about Astellas Pharma Canada, Inc., please visit
the corporate website: www.astellas.ca
SOURCE: Astellas Pharma Canada, Inc.
For further information:
Astellas Pharma Canada, Inc.
Executive Director, CUA Office of Education
Canadian Urological Association
(514) 395-0376 ext. 44